Yellow card scheme, Don’t wait for someone else to report it
https://www.gov.uk/drug-safety-update/yellow-card-please-help-to-reverse-the-decline-in-reporting-of-suspected-adverse-drug-reactions
It is estimated that only 10% of serious reactions and between 2 and 4% of non-serious reactions are reported.
Yellow card government site, just a click away
https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting
As of 23 November 2022, (UK)
Pfizer/BioNTech, monovalent and bivalent
177,925 Yellow Cards have been reported
AstraZeneca
246,866 have been reported
Moderna, monovalent and bivalent
47,045 have been reported
Novavax
52 reports
Brand of vaccine was not specified
2,130 reports
Total reports
474,018
Overall reporting rate
Around 2 to 5 Yellow Cards per 1,000 doses administered
In the 28 days
Pfizer/BioNTech, + 2,499 reports
AstraZeneca, + 228
Moderna, + 1,099
Novavax, + 15
Brand not specified, + 154
For all COVID-19 vaccines
injection-site reactions (sore arm for example)
generalised symptoms such as ‘flu-like’ illness
headache, chills, fatigue (tiredness), nausea (feeling sick), fever, dizziness, weakness, aching muscles, rapid heartbeat
they may be reported more frequently in younger adults
Overall, our advice remains that the benefits of the vaccines outweigh the risks in the majority of people.
The benefits of the vaccines in preventing COVID-19 and serious complications associated with COVID-19 far outweigh any currently known side effects in the majority of patients.
https://wchh.onlinelibrary.wiley.com/doi/pdf/10.1002/psb.1789
Google YT guidelines
https://support.google.com/youtube/answer/9891785
Claims that an approved COVID-19 vaccine will cause death, infertility, miscarriage, autism, or contraction of other infectious diseases
https://www.gov.uk/government/publications/regulatory-approval-of-covid-19-vaccine-moderna/information-for-healthcare-professionals-on-covid-19-vaccine-moderna
4.4 Special warnings and precautions for use
Hypersensitivity and anaphylaxis
Anaphylaxis has been reported in individuals who have received Spikevax.
Close observation for at least 15 minutes is recommended following vaccination.
Myocarditis and pericarditis
There is an increased risk for myocarditis and pericarditis following vaccination with Spikevax.
Few days, primarily occurred within 14 days,
more often after the second dose,
more often in younger males
risk profile appears to be similar for the second and the third dose
Available data suggest that the course of myocarditis and pericarditis following vaccination is not different from myocarditis or pericarditis in general.
Healthcare professionals should be alert to the signs and symptoms of myocarditis and pericarditis.
Vaccinated individuals should be instructed to seek immediate medical attention if they develop symptoms indicative of myocarditis or pericarditis,
such as (acute or persisting) chest pain, shortness of breath or palpitations following vaccination.
Healthcare professionals should consult guidance and/or specialists to diagnose and treat this condition.
Who can get a COVID-19 vaccine
https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/coronavirus-vaccine/
Everyone aged 5 (on or before 31 August 2022) and over can get a 1st and 2nd dose of the COVID-19 vaccine.
People aged 16 and over, and some children aged 12 to 15, can also get a booster dose.
Hypertension after COVID-19 vaccination
https://pubmed.ncbi.nlm.nih.gov/34985455/
Italian research
Source